Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16679848 | 0.90 | ITGB3 (0.47) | ACEACE2MMECPA1ITGB3 | |
| SCHEMBL3663289 | 0.86 | ACE (0.51) | ACEACE2MMECPA1ITGB3 | |
| SCHEMBL23013983 | 0.85 | MME (0.45) | ACEACE2MMECPA1ITGB3 | |
| SCHEMBL5085119 | 0.85 | CTSK (0.50) | ACEACE2ITGB3ITGA2BITGAV | |
| SCHEMBL23013984 | 0.85 | MME (0.45) | ACEACE2MMECPA1ITGB3 | |
| SCHEMBL29481430 | 0.85 | MME (0.45) | ACEACE2MMECPA1ITGB3 | |
| SCHEMBL4785709 | 0.84 | MME (0.50) | ACEMMEITGB3ITGA2BITGB1 | |
| SCHEMBL5262273 | 0.84 | ITGB3 (0.44) | ACEACE2ITGB3ITGA2BITGB1 | |
| SCHEMBL5181822 | 0.84 | ITGB1 (0.52) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL8023605 | 0.84 | ITGB1 (0.52) | ITGB3ITGA2BITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | ACE 838/4885ACE2 1258/4885MME 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.